文献速递白血病

儿童白血病中风险适配与霉菌特异性抗真菌预防的获益

Benefits of risk-adapted and mould-specific antifungal prophylaxis in childhood leukaemia.
PubMed 文献 · Br J Haematol · 2020-07-04

这项回顾性单中心研究比较了198例急性白血病患儿(中位年龄5.3岁)不同抗真菌预防策略的耐受性与结局。2010年前多数患者接受氟康唑预防,此后改为仅高危患者使用脂质体两性霉素B(L-AMB);L-AMB下长春新碱神经毒性显著减轻,2011年风险适配后侵袭性真菌感染完全预防。

要点

  • L-AMB预防下严重便秘患者比例较氟康唑期下降(15.4% vs 3.7%,P=0.01)。
  • 多烯类治疗患者排便频率增加至38%(P=0.005)。
  • 2011年风险适配后侵袭性真菌感染完全预防(P=0.007)。

核心结论

  • L-AMB预防对儿童白血病患者有益,与氟康唑相比提供有效抗真菌活性且耐受性改善。
  • 作者认为风险适配抗真菌治疗的潜在影响应纳入当前儿童白血病预防指南。

研究设计与样本

  • 回顾性单中心研究,纳入198例急性白血病患儿,中位年龄5.3岁。
  • 2010年前多数患者接受氟康唑预防,此后改为脂质体两性霉素B(L-AMB)并仅限高危患者。

主要发现

  • L-AMB下长春新碱诱导神经毒性显著减轻,严重便秘患者比例下降(15.4% vs 3.7%,2010年12月31日前 vs 后,P=0.01)。
  • 多烯类治疗患者排便频率增加至38%(P=0.005)。
  • 2011年前10例患者发生确诊侵袭性真菌感染,多数为曲霉属感染;2011年风险适配后侵袭性真菌感染完全预防(P=0.007)。

临床怎么用

  • 作者认为L-AMB预防对儿童白血病患者有益,风险适配抗真菌治疗的影响应纳入当前预防指南。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fluconazole is one of the most commonly used drugs for antifungal prophylaxis in childhood leukaemia. However, its interaction with vincristine may induce neuropathy and the emergence of antifungal drug resistance contributes to substantial mortality caused by invasive fungal infections (IFIs). In a retrospective single-centre study, we compared tolerability and outcome of different antifungal prophylaxis strategies in 198 children with acute leukaemia (median age 5·3 years). Until 2010, antifungal prophylaxis with fluconazole was offered to most of the patients and thereafter was replaced by liposomal amphotericin-B (L-AMB) and restricted to high-risk patients only. Vincristine-induced neurotoxicity was significantly reduced under L-AMB, as the percentage of patients with severe constipation decreased (15·4% vs. 3·7%, before vs. after 31 December·2010, P = 0·01) and stool frequency increased by up to 38% in polyene-treated patients (P = 0·005). Before 2011, 10 patients developed confirmed IFIs, most of them were infected with Aspergillus species. After risk adaption in 2011, IFIs were completely prevented (P = 0·007). L-AMB prophylaxis is beneficial in childhood leukaemia patients, as it offers effective antifungal activity with improved tolerability as compared to fluconazole. The potential impact of our risk-adapted antifungal treatment should be included in current prophylaxis guidelines for childhood leukaemia.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Meryk A, Kropshofer G, Hutter J, et al. Benefits of risk-adapted and mould-specific antifungal prophylaxis in childhood leukaemia. Br J Haematol. 2020. PMID: 32621534. doi:10.1111/bjh.16931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。